Tenderwize
Back to tender search

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 195 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Mepolizumab, ATC R03DX09

60/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

20 / 100

Risk factors

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for the active substance Mepolizumab (ATC R03DX09).
  • Contracts are open to all interested pharmaceutical companies under uniform terms.
Show full summary

Open House model for non-exclusive discount agreements on Mepolizumab (ATC R03DX09) offered by AOK Rheinland-Pfalz/Saarland. Any pharmaceutical company with authorized and marketable Mepolizumab products in Germany can join. Contracts run up to 24 months from May 1, 2025 to April 30, 2027, with rolling join dates. The procedure is not subject to EU procurement law despite using a standard notice form. No estimated value is provided.

Risks

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only authorized and marketable medicinal products in Germany may be supplied.
  • Proof of authorization and marketability required (Lauer-Taxe listing or AMIce database extract).

Certifications

  • For products not yet listed, additional documentation (e.g., approval certificate) must be provided.

Award Criteria

Lot 1

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Buyer

Lots (1)

LOT-0001

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

Non-exclusive discount agreement for Mepolizumab. Any pharmaceutical company meeting eligibility can sign up. Contracts valid until April 30, 2027. The AOK reserves the right to replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
12 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
165250-2025

Documents (1)

Similar tenders